If ex-Chairman of National Security Committee won't show up for interrogation, he will be brought by forceSon of ex-president calls events in Koi-Tash planned provocation

Ebola drugs show 90% survival rate in breakthrough trial

 

Фотографии: akipress.kg

August 13, 2019, 13:06       Источник akipress.kg       Комментарии

AKIPRESS.COM - Ebola may soon be a "preventable and treatable" disease after a trial of two drugs showed significantly improved survival rates, scientists have said, BBC reports.
Four drugs were trialled on patients in the Democratic Republic of Congo, where there is a major outbreak of the virus.
More than 90% of infected people can survive if treated early with the most effective drugs, the research showed.
The drugs will now be used to treat all patients with the disease in DR Congo, according to health officials.
The US National Institute of Allergy and Infectious Diseases (NIAID), which co-sponsored the trial, said the results are "very good news" for the fight against Ebola.
The drugs, named REGN-EB3 and mAb114, work by attacking the Ebola virus with antibodies, neutralising its impact on human cells.
They are the "first drugs that, in a scientifically sound study, have clearly shown a significant diminution in mortality" for Ebola patients, said Dr Anthony Fauci, director of NIAID.
REGN-EB3 and mAb114 were developed using antibodies harvested from survivors of Ebola, which has killed more than 1,800 people in DR Congo in the past year.

Ссылка на новость:
https://for.kg/news-598256-en.html

Читайте также

Hundreds of fish wash up as a result of high-mountain lake breakthrough

After Turkmen oil breakthrough, Vitol adds products to portfolio

Russia to pay Kazakhstan $15 per barrel for tainted oil in crisis breakthrough

First baby born through new egg-freezing technique in fertility breakthrough

 

SAPE:

 

АГРОПОРТАЛ КЫРГЫЗСТАНА, НОВОСТИ СЕЛЬСКОГО ХОЗЯЙСТВА
Обучение ювелирному делу в Бишкеке
МСН Общественно-политическая газета

18+

FOR.kg - Кыргызстан новости, пресса

FOR.kg search news service (news aggregator, media aggregator)

Read first Agreement on the use of the FOR.kg search site

When using materials from the FOR.kg - reference to the source is required

For all questions please contact customer support

Top.Mail.Ru